Dr. Goyal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Summary
- Dr. Lipika Goyal is medical oncologist in Palo Alto, CA and serves as the Director of Gastrointestinal Oncology at the Stanford Cancer Center. She received her medical degree from Harvard Medical School and has been in practice 11 years. She is runs clinical trials and does research in cholangiocarcinoma, and hepatocellular carcinoma. She has more than 100 publications and over 500 citings.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2013- Brigham and Women's HospitalResidency, Internal Medicine, 2007 - 2010
Harvard Medical SchoolClass of 2007
Certifications & Licensure
CA State Medical License 2023 - 2025
MA State Medical License 2012 - 2023
Clinical Trials
- Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Start of enrollment: 2019 Oct 07
Publications & Presentations
PubMed
- Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD.Batul Kaj-Carbaidwala, Johan Fevery, Douglas G Adler, Annika Bergquist, Lissy de Ridder
Journal of Pediatric Gastroenterology and Nutrition. 2024-12-20 - Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment.Romain Désert, Lipika Goyal, Thomas F Baumert
Gut. 2024-12-06 - Plain language summary: an analysis of the safety of futibatinib treatment in people with different types of cancer.Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do-Youn Oh, John A Bridgewater
Future Oncology. 2024-10-28
Journal Articles
- A Phase II and Biomarker Study of Sorafenib Combined with FOLFOX in Patients with Advanced Hepatocellular Carcinoma (HCC)Hui Zheng, Rakesh K Jain, Lipika Goyal, Andrew X Zhu, Clinical Cancer Research
Press Mentions
Taiho Oncology Announces Publication in the New England Journal of Medicine of Pivotal Data for Futibatinib in Previously Treated Patients with Metastatic Intrahepatic CholangiocarcinomaJanuary 18th, 2023- FDA Approves Taiho's LYTGOBI® (Futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic CholangiocarcinomaSeptember 30th, 2022
- Taiho Oncology Announces Updated Efficacy and Safety Data for Futibatinib in Cholangiocarcinoma at 2022 ASCO Annual MeetingJune 3rd, 2022
- Join now to see all
Other Languages
- Spanish, Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
